Salt form of a human histone methyltransferase EZH2 inhibitor
US-9394283-B2 · Jul 19, 2016 · US
Aryl-or heteroaryl-substituted benzene compounds
US12161645B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12161645-B2 |
| Application number | US-202418606903-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 15, 2024 |
| Priority date | Apr 13, 2011 |
| Publication date | Dec 10, 2024 |
| Grant date | Dec 10, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating follicular lymphoma comprising administering to a human subject in need thereof a compound of the following formula: or a pharmaceutically acceptable salt thereof. 2. The method of claim 1 , wherein the compound is: 3. The method of claim 1 , wherein the compound is a pharmaceutically acceptable salt of: 4. The method of claim 1 , wherein the compound is administered orally to the human subject in need thereof. 5. The method of claim 4 , wherein the compound is administered twice daily. 6. The method of claim 5 , wherein the compound is administered in an amount of from about 0.1 mg/day to about 3 g/day. 7. The method of claim 3 , wherein the pharmaceutically acceptable salt is a hydrobromic acid salt. 8. The method of claim 7 , wherein the compound is administered orally to the human subject in need thereof. 9. The method of claim 8 , wherein the compound is administered twice daily. 10. The method of claim 9 , wherein the compound is administered in an amount of from about 0.1 mg/day to about 3 g/day.
Assignees
Inventors
Classifications
containing three or more hetero rings · CPC title
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms · CPC title
with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring · CPC title
- C07D413/12Primary
linked by a chain containing hetero atoms as chain links · CPC title
Bridged systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12161645B2 cover?
- The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-thera…
- Who is the assignee on this patent?
- Epizyme Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D413/12. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).